Kairos Pharma, Ltd. (KAPA) is a publicly traded Healthcare sector company. As of May 21, 2026, KAPA trades at $0.49 with a market cap of $10.28M and a P/E ratio of -1.70. KAPA moved +5.13% today. Year to date, KAPA is -34.05%; over the trailing twelve months it is -13.05%. Its 52-week range spans $0.40 to $3.25. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces KAPA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kairos Pharma Signs Term Sheet to Acquire Two Clinical Oncology Assets: Kairos Pharma signed a term sheet to acquire two clinical oncology assets from Celyn Therapeutics, subject to definitive agreements and approvals. The assets will expand Kairos’s clinical pipeline and target key solid tumor indications.
| Metric | Value |
|---|---|
| Price | $0.49 |
| Market Cap | $10.28M |
| P/E Ratio | -1.70 |
| EPS | $-0.30 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.25 |
| 52-Week Low | $0.40 |
| Volume | 1.61K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-5.45M |
| Gross Margin | 0.00% |
2 analysts cover KAPA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.